Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the prognostic value of clinical and biological factors in patients with refractory/relapsed Diffuse Large B-Cell Lymphoma.
The main aim of this study is to compare the prognostic value of R-IPI at diagnosis and relapse, relating it with the obtained response after second line
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| refractory/relapsed LDCBG | patients with refractory/relapsed diffuse large B-cell lymphoma |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| R-IPI Index (Revised International Prognostic Index) | Data will be recorded from diagnosis to second line response, an expected average of 7 months | At diagnoses |
| R-IPI Index (Revised International Prognostic Index) | The IPI is based on the evaluation of 5 clinical factors: age > 60 years Ann Arbor stage III or IV disease > 1 extra nodal site European Cooperative Oncology Group performance status (ECOG PS) _ 2, increased serum LDH (lactate dehydrogenase) levels Revised IPI (R-IPI) evaluates the same parameters, but groups them differently to form 3 prognostic groups of patients with significantly different progression-free survival and overall survival outcomes. | At the beginning of the 2nd line of treatment, an average of 2 years |
| Predictive Value of R-IPI at Diagnosis | At diagnosis |
| Measure | Description | Time Frame |
|---|---|---|
| Bcl-2 Expression | immunohistochemical reaction of cells with Bcl-2 antibody | At diagnosis |
| Bcl-2 Expression | immunohistochemical reaction of cells with Bcl-2 antibody |
Not provided
Not provided
Not provided
Not provided
Patients with refractory/relapsed diffuse large B-cell lymphoma
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Carlos Panizo, PhD | Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital de Elda | Elda | Alicante | Spain | |||
| H. U. Germans Trias i Pujol |
Not provided
Recruitment was carried out between April 2009 and January 2011 in Hematology Departments of 56 Spanish Hospitals
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Refractory/Relapsed LDCBG (Diffuse Large-B-cell Lymphoma) | patients with refractory/relapsed diffuse large B-cell lymphoma |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
| At the beginning of the 2nd line of treatment |
| Bcl-6 Expression | immunohistochemical reaction of cells with Bcl-6 antibody | At diagnosis |
| Bcl-6 Expression | immunohistochemical reaction of cells with Bcl-6 antibody | At the beginning of the second line of treatment |
| p-53 Expression | immunohistochemical reaction of cells with p-53 antibody | At diagnosis |
| p53 Expression | immunohistochemical reaction of cells with p-53 antibody | At the beginning of the 2nd line of treatment |
| Multiple Myeloma Oncogene 1 (MUM-1) Expression | immunohistochemical reaction of cells with MUM-1 antibody | At diagnosis |
| MUM-1 Expression | immunohistochemical reaction of cells with MUM-1 antibody | At the beginning of the 2nd line of treatment |
| Eastern Cooperative Oncology Group Performance Status (ECOG) Performance Status | ECOG=0: Fully active, able to carry on all pre-disease performance without restriction ECOG=5: Exitus | At the beginning of the 2nd line of treatment |
| Ann Arbor Staging | Ann Arbor=I: Best condition Ann Arbor=IV: Worst condition | At the beginning of the 2nd line of treatment |
| Response to First Line of Treatment | Complete Response (CR), Disappearance of all target lesions for at least 8 weeks. Partial response (PR): At least a 50% dicrease in the sum of the products of two measurements (the maximum diameter of a tumor and the largest diameter perpendicular to this maximum diameter) of 6 biggest individual tumors. Not increased of measure of other tumors, spleen or liver Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started Progressive Disease (PD): At least a 50% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions during or at the end of the treatment. | After first line treatment |
| Response to Second Line of Treatment | Complete Response (CR), Disappearance of all target lesions for at least 8 weeks. Partial response (PR): At least a 50% dicrease in the sum of the products of two measurements (the maximum diameter of a tumor and the largest diameter perpendicular to this maximum diameter) of 6 biggest individual tumors. Not increased of measure of other tumors, spleen or liver Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started Progressive Disease (PD): At least a 50% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions during or at the end of the treatment. | After second line of treatment |
| Relationship Between Global Response Rate to 2nd (Second) Line of Treatment and Bcl-2 Expression at Diagnosis | Global response rate was assessed using the National Cancer Institute-sponsored Working Group guidelines. Responses are: complete response, partial response, stable disease, progression and relapse | At diagnosis |
| Relationship Between Global Response Rate to 2nd Line of Treatment and Bcl-6 Expression at Diagnosis | Global response rate was assessed using the National Cancer Institute-sponsored Working Group guidelines. Responses are: complete response, partial response, stable disease, progression and relapse | At diagnosis |
| Relationship Between Global Response Rate to 2nd Line of Treatment and p53 Expression at Diagnosis | Global response rate was assessed using the National Cancer Institute-sponsored Working Group guidelines. Responses are: complete response, partial response, stable disease, progression and relapse | At diagnosis |
| Relationship Between Global Response Rate to 2nd Line of Treatment and Multiple Myeloma Oncogene 1 (MUM1) Expression at Diagnosis | Global response rate was assessed using the National Cancer Institute-sponsored Working Group guidelines. Responses are: complete response, partial response, stable disease, progression and relapse | At diagnosis |
| Badalona |
| Barcelona |
| Spain |
| Hospital Clinic i Provincial | Barcelona | Barcelona | Spain |
| Hospital del Mar | Barcelona | Barcelona | Spain |
| Hospital Vall D'Hebrón | Barcelona | Barcelona | Spain |
| Hospital General de Granollers | Granollers | Barcelona | Spain |
| ICO-DYR | L'Hospitalet de Llobregat | Barcelona | Spain |
| Althaia | Manresa | Barcelona | Spain |
| Hospital de Mataró | Mataró | Barcelona | Spain |
| Hospital Parc Taulí | Sabadell | Barcelona | Spain |
| H. Sierrallana | Torrelavega | Cantabria | Spain |
| Hospital General del SAS de Jerez | Jerez de la Frontera | Cádiz | Spain |
| Institut Catalá d'Oncologia de Girona | Girona | Gerona | Spain |
| H.U. Virgen de las Nieves | Granada | Granada | Spain |
| Hospital Galdakao | San Sebastián | Guipuzcoa | Spain |
| Complejo Hospitalario de Jaén | Jaén | Jaén | Spain |
| C.H.U. A Coruña | A Coruña | La Coruña | Spain |
| H. Clínico U. Santiago de Compostela | Santiago de Compostela | La Coruña | Spain |
| Hospital San Pedro | Logroño | La Rioja | Spain |
| Hospital de León | León | León | Spain |
| Hospital Xeral | Lugo | Lugo | Spain |
| Hospital Universitario Arnau de Vilanova | Lleida | Lérida | Spain |
| H.U. Fundación Alcorcón | Alcorcón | Madrid | Spain |
| H.U.de Getafe | Getafe | Madrid | Spain |
| H. Severo Ochoa | Leganés | Madrid | Spain |
| H. Ramón y Cajal | Madrid | Madrid | Spain |
| H. U. La Princesa | Madrid | Madrid | Spain |
| H.G.U. Gregorio Marañón | Madrid | Madrid | Spain |
| H.U. La Paz | Madrid | Madrid | Spain |
| Hospital 12 de Octubre | Madrid | Madrid | Spain |
| MD Anderson | Madrid | Madrid | Spain |
| Hospital Son Llatzer | Mallorca | Mallorca | Spain |
| H.U. Virgen de la Arrixaca | Murcia | Murcia | Spain |
| Hospital Morales Messeguer | Murcia | Murcia | Spain |
| Hospital Costa del Sol | Marbella | Málaga | Spain |
| H. Carlos Haya | Málaga | Málaga | Spain |
| Clínica Universitaria de Navarra | Pamplona | Navarre | Spain |
| Hospital de Navarra | Pamplona | Navarre | Spain |
| Complexo Hospitalario de Ourense | Ourense | Orense | Spain |
| Hospital Universitario Son Dureta | Palma de Mallorca | Palma de Mallorca | Spain |
| Hospital de Cabueñes | Gijón | Principality of Asturias | Spain |
| H. U. Central de Asturias | Oviedo | Principality of Asturias | Spain |
| H. Universitario de Salamanca | Salamanca | Salamanca | Spain |
| H. General de Segovia | Segovia | Segovia | Spain |
| H.U. Nuestra Señora de Valme | Seville | Sevilla | Spain |
| H. Universitario de Canarias | San Cristóbal de La Laguna | Tenerife | Spain |
| H. Nuestra Señora del Prado | Talavera de la Reina | Toledo | Spain |
| H. Arnau de Vilanova | Valencia | Valencia | Spain |
| H. Clínico de Valencia | Valencia | Valencia | Spain |
| H. Dr. Peset | Valencia | Valencia | Spain |
| H. Río Hortega | Valladolid | Valladolid | Spain |
| Hospital Clínico Universitario Valladolid | Valladolid | Valladolid | Spain |
| H. Basurto | Bilbao | Vizcaya | Spain |
| H. Virgen de La Concha | Zamora | Zamora | Spain |
| H. Txagorritxu | Vitoria-Gasteiz | Álava | Spain |
| H. Nuestra Señora de Sonsoles | Ávila | Ávila | Spain |
| COMPLETED |
|
| NOT COMPLETED |
|
|
12 patients were not included in the data analysis for not fulfilling selection criteria
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Refractory/Relapsed LDCBG | patients with refractory/relapsed diffuse large B-cell lymphoma |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| ||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||||||
| Ann Arbor Staging | Ann Arbor=I: Best condition Ann Arbor=IV: Worst condition | Number | participants |
| ||||||||||||||||||||||
| ECOG Performance Status (Eastern Cooperative Oncology Group Performance Status) | ECOG=0: Fully active, able to carry on all pre-disease performance without restriction ECOG=5: Exitus | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | R-IPI Index (Revised International Prognostic Index) | Data will be recorded from diagnosis to second line response, an expected average of 7 months | Posted | Number | percentage of participants | At diagnoses |
|
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Bcl-2 Expression | immunohistochemical reaction of cells with Bcl-2 antibody | Posted | Number | percentage of participants | At diagnosis |
|
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Bcl-2 Expression | immunohistochemical reaction of cells with Bcl-2 antibody | Posted | Number | participants | At the beginning of the 2nd line of treatment |
|
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Bcl-6 Expression | immunohistochemical reaction of cells with Bcl-6 antibody | Posted | Number | participants | At diagnosis |
|
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Bcl-6 Expression | immunohistochemical reaction of cells with Bcl-6 antibody | Posted | Number | percentage of participants | At the beginning of the second line of treatment |
|
|
| |||||||||||||||||||||||||||||||||||||
| Primary | R-IPI Index (Revised International Prognostic Index) | The IPI is based on the evaluation of 5 clinical factors: age > 60 years Ann Arbor stage III or IV disease > 1 extra nodal site European Cooperative Oncology Group performance status (ECOG PS) _ 2, increased serum LDH (lactate dehydrogenase) levels Revised IPI (R-IPI) evaluates the same parameters, but groups them differently to form 3 prognostic groups of patients with significantly different progression-free survival and overall survival outcomes. | Posted | Number | percentage of patients | At the beginning of the 2nd line of treatment, an average of 2 years |
|
| ||||||||||||||||||||||||||||||||||||||
| Secondary | p-53 Expression | immunohistochemical reaction of cells with p-53 antibody | Posted | Number | percentage of participants | At diagnosis |
|
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | p53 Expression | immunohistochemical reaction of cells with p-53 antibody | Posted | Number | percentage of participants | At the beginning of the 2nd line of treatment |
|
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Multiple Myeloma Oncogene 1 (MUM-1) Expression | immunohistochemical reaction of cells with MUM-1 antibody | Posted | Number | percentage of participants | At diagnosis |
|
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | MUM-1 Expression | immunohistochemical reaction of cells with MUM-1 antibody | Posted | Number | percentage of participants | At the beginning of the 2nd line of treatment |
|
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Eastern Cooperative Oncology Group Performance Status (ECOG) Performance Status | ECOG=0: Fully active, able to carry on all pre-disease performance without restriction ECOG=5: Exitus | Posted | Number | participants | At the beginning of the 2nd line of treatment |
|
| ||||||||||||||||||||||||||||||||||||||
| Secondary | Ann Arbor Staging | Ann Arbor=I: Best condition Ann Arbor=IV: Worst condition | Posted | Number | percentage of patients | At the beginning of the 2nd line of treatment |
|
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Response to First Line of Treatment | Complete Response (CR), Disappearance of all target lesions for at least 8 weeks. Partial response (PR): At least a 50% dicrease in the sum of the products of two measurements (the maximum diameter of a tumor and the largest diameter perpendicular to this maximum diameter) of 6 biggest individual tumors. Not increased of measure of other tumors, spleen or liver Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started Progressive Disease (PD): At least a 50% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions during or at the end of the treatment. | Posted | Number | participants | After first line treatment |
|
| ||||||||||||||||||||||||||||||||||||||
| Secondary | Response to Second Line of Treatment | Complete Response (CR), Disappearance of all target lesions for at least 8 weeks. Partial response (PR): At least a 50% dicrease in the sum of the products of two measurements (the maximum diameter of a tumor and the largest diameter perpendicular to this maximum diameter) of 6 biggest individual tumors. Not increased of measure of other tumors, spleen or liver Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started Progressive Disease (PD): At least a 50% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions during or at the end of the treatment. | Posted | Number | participants | After second line of treatment |
|
| ||||||||||||||||||||||||||||||||||||||
| Primary | Predictive Value of R-IPI at Diagnosis | Posted | Number | participants | At diagnosis |
|
|
| ||||||||||||||||||||||||||||||||||||||
| Secondary | Relationship Between Global Response Rate to 2nd (Second) Line of Treatment and Bcl-2 Expression at Diagnosis | Global response rate was assessed using the National Cancer Institute-sponsored Working Group guidelines. Responses are: complete response, partial response, stable disease, progression and relapse | Posted | Number | participants | At diagnosis |
|
| ||||||||||||||||||||||||||||||||||||||
| Secondary | Relationship Between Global Response Rate to 2nd Line of Treatment and Bcl-6 Expression at Diagnosis | Global response rate was assessed using the National Cancer Institute-sponsored Working Group guidelines. Responses are: complete response, partial response, stable disease, progression and relapse | Posted | Number | participants | At diagnosis |
|
| ||||||||||||||||||||||||||||||||||||||
| Secondary | Relationship Between Global Response Rate to 2nd Line of Treatment and p53 Expression at Diagnosis | Global response rate was assessed using the National Cancer Institute-sponsored Working Group guidelines. Responses are: complete response, partial response, stable disease, progression and relapse | Posted | Number | participants | At diagnosis |
|
| ||||||||||||||||||||||||||||||||||||||
| Secondary | Relationship Between Global Response Rate to 2nd Line of Treatment and Multiple Myeloma Oncogene 1 (MUM1) Expression at Diagnosis | Global response rate was assessed using the National Cancer Institute-sponsored Working Group guidelines. Responses are: complete response, partial response, stable disease, progression and relapse | Posted | Number | participants | At diagnosis |
|
| ||||||||||||||||||||||||||||||||||||||
| Post-Hoc | Relationship Between Global Response Rate to 2nd Line of Treatment and Absolute Lymphocyte Count on Relapse | Global response rate was assessed using the National Cancer Institute-sponsored Working Group guidelines. Responses are: complete response, partial response, stable disease, progression and relapse | Posted | Number | participants | At relapse |
|
| ||||||||||||||||||||||||||||||||||||||
| Post-Hoc | Relationship Between Global Response Rate to 2nd Line of Treatment and Lymphocyte/Monocyte Rate on Relapse | Global response rate was assessed using the National Cancer Institute-sponsored Working Group guidelines. Responses are: complete response, partial response, stable disease, progression and relapse | Posted | Number | participants | At relapse |
|
| ||||||||||||||||||||||||||||||||||||||
| Post-Hoc | Relationship Between Global Response Rate to 2nd Line of Treatment and Beta-2 Microglobulin at Relapse | Global response rate was assessed using the National Cancer Institute-sponsored Working Group guidelines. Responses are: complete response, partial response, stable disease, progression and relapse | Posted | Mean | Standard Deviation | mg/100ml | At relapse |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Refractory/Relapsed LDCBG | patients with refractory/relapsed diffuse large B-cell lymphoma | 18 | 146 | 44 | 146 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Neutropenia | Blood and lymphatic system disorders |
| |||
| Leucopenia | Blood and lymphatic system disorders |
| |||
| Trombocitopenia | Blood and lymphatic system disorders |
| |||
| Anemia | Blood and lymphatic system disorders |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Fatigue | General disorders |
| |||
| Gastrointestinal symptoms | Gastrointestinal disorders |
| |||
| Anorexia | Metabolism and nutrition disorders |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Carlos Panizo | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (GELTAMO) | + 34 948 25 54 00 | cpanizo@unav.es |
| ID | Term |
|---|---|
| D016403 | Lymphoma, Large B-Cell, Diffuse |
| ID | Term |
|---|---|
| D016393 | Lymphoma, B-Cell |
| D008228 | Lymphoma, Non-Hodgkin |
| D008223 | Lymphoma |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided
| III |
|
| IV |
|
| ECOG 2 |
|
| ECOG 3 |
|
| ECOG 4 |
|
| Title | Measurements |
|---|---|
|
| Positive |
|
| Negative |
|
| Not available |
|
| Positive |
|
| Negative |
|
| Not Available |
|
| Positive |
|
| Negative |
|
| Not available |
|
| Positive |
| |||||
| Negative |
| |||||
| Not available |
|
|
| Positive |
|
| Negative |
|
| Not available |
|
| Positive |
| |||||
| Negative |
| |||||
| Not available |
|
| Positive |
| |||||
| Negative |
| |||||
| Not available |
|
| Positive |
| |||||
| Negative |
| |||||
| Not available |
|
| Title |
|---|
| Denominators |
|---|
| Categories |
|---|
| ECOG 0 |
| |||||
| ECOG 1 |
| |||||
| ECOG 2 |
| |||||
| ECOG 3 |
| |||||
| ECOG 4 |
|
| I |
| |||||
| II |
| |||||
| III |
| |||||
| IV |
|
|
|
|
| No global response to 2nd line + very good prognos |
|
| Global response to 2nd line + good prognosis |
|
| No global response to 2nd line + good prognosis |
|
| Global response to 2nd line + poor prognosis |
|
| No global response to 2nd line + poor prognosis |
|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
| Global response to 2nd line + Bcl-2 + |
| |||||
| Global response to 2nd line + Bcl-2 - |
| |||||
| No global response to 2nd line + Bcl-2 + |
| |||||
| No global response to 2nd line + Bcl-2 - |
| |||||
| Global response to 2nd line +Bcl-2 ND |
| |||||
| No global response to 2nd line + Bcl-2 ND |
|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
| Global response to 2nd line + Bcl-6 + |
| |||||
| Global response to 2nd line + Bcl-6 - |
| |||||
| Global response to 2nd line + Blc-6 ND |
| |||||
| No global response to 2nd line + Bcl-6 + |
| |||||
| No global response to 2nd line + Bcl-6 - |
| |||||
| No global response to 2nd line + Bcl-6 ND |
|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
| Global response to 2nd line + p53+ |
| |||||
| Global response to 2nd line + p53- |
| |||||
| No global response to 2nd line + p53+ |
| |||||
| No global response to 2nd line + p53- |
| |||||
| Global response to 2nd line + p53 ND |
| |||||
| Global response to 2nd line + p53 - ND |
|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
| Global response to 2nd line + MUM1 + |
| |||||
| Global response to 2nd line + MUM1 - |
| |||||
| No global response to 2nd line + MUM1 + |
| |||||
| No global response to 2nd line + MUM1 - |
| |||||
| Global response to 2nd line + MUM1 ND |
| |||||
| No global response to 2nd line + MUM1 ND |
|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
| Global response to 2nd line + lymphocyte <1 |
| |||||
| Global response to 2nd line + lymphocyte >=1 |
| |||||
| No global response to 2nd line + lymphocyte <1 |
| |||||
| No global response to 2nd line + lymphocyte >=1 |
|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
| Global response to 2nd line + ratio <=2.6 |
| |||||
| Global response to 2nd line + ratio >2.6 |
| |||||
| No global response to 2nd line + ratio <=2.6 |
| |||||
| No global response to 2nd line + ratio >2.6 |
|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
| Global response to 2nd line |
| |||||
| No global response to 2nd line |
|